FOSTER CITY, California, USA, June 2, 2026
Gilead Sciences has announced positive topline results from the Phase 3 IDEAL clinical trial, demonstrating that Livdelzi® (seladelpar) achieved statistically significant improvements in alkaline phosphatase (ALP) normalization, a critical marker of disease progression in primary biliary cholangitis (PBC). The 52-week study evaluated patients with inadequately controlled disease who continued to experience elevated ALP levels despite treatment with ursodeoxycholic acid (UDCA) or who were unable to tolerate the standard therapy. The findings provide further evidence that ALP normalization may be an achievable and clinically meaningful treatment goal for patients living with this chronic autoimmune liver disease. The results also reinforce Livdelzi’s growing clinical profile and support ongoing efforts to improve long-term outcomes for individuals at risk of progressive liver damage, transplantation, and liver-related complications.
Phase 3 IDEAL Trial Demonstrates Significant ALP Normalization
The IDEAL trial was designed to evaluate Livdelzi in adults with PBC whose ALP levels remained elevated above normal but below 1.67 times the upper limit of normal despite existing treatment. This patient population has traditionally been underrepresented in randomized clinical studies, despite being frequently encountered in real-world clinical practice. The trial met its primary endpoint, showing that significantly more patients receiving Livdelzi achieved a composite endpoint of ALP normalization and at least a 15% reduction from baseline compared with placebo after 52 weeks of treatment.
ALP is widely recognized as a key biochemical marker associated with disease activity and long-term outcomes in PBC. Elevated ALP levels have been linked to increased risks of liver transplantation, disease progression, and mortality, making normalization of this marker an increasingly important therapeutic objective within hepatology. The results add to a growing body of evidence supporting the role of seladelpar in achieving meaningful disease control in patients who remain inadequately managed with current treatment approaches.
Expanding Treatment Options for an Underserved PBC Population
Advertisement
Primary biliary cholangitis is a chronic autoimmune disease that gradually destroys the bile ducts within the liver, leading to inflammation, fibrosis, and potentially liver failure if left untreated. The condition affects approximately 130,000 Americans, with women representing the majority of diagnosed cases. Common symptoms include severe fatigue and chronic itching, both of which can significantly reduce quality of life. Despite available therapies, many patients fail to achieve optimal biochemical control, creating a substantial unmet medical need.
Livdelzi, an oral PPAR-delta agonist, has demonstrated anti-inflammatory, anticholestatic, antipruritic, and antifibrotic effects in both preclinical and clinical studies. Previous Phase 3 RESPONSE trial data established Livdelzi as the first and only treatment to demonstrate statistically significant reductions in both disease markers and pruritus versus placebo. The IDEAL findings now extend this evidence to a broader patient population, further supporting its therapeutic value across different stages of disease management.
Safety Profile Supports Long-Term Clinical Use
In addition to efficacy outcomes, the IDEAL study confirmed that the safety profile of Livdelzi remained consistent with previously reported clinical trials. No new safety concerns were identified during the 52-week evaluation period, reinforcing confidence in the medicine’s long-term tolerability. Gilead emphasized that advancing liver disease treatment requires continued innovation and evidence generation to address persistent unmet needs among patients. The company plans to present the full dataset at an upcoming medical congress and engage with global regulatory authorities regarding the implications of the findings.
As the field increasingly embraces ALP normalization as a key treatment target, the IDEAL trial positions Livdelzi as an important therapeutic option for patients seeking improved disease control and better long-term liver health outcomes. The latest data also strengthen Gilead’s expanding leadership position in liver disease research and underscore the company’s commitment to developing therapies that deliver meaningful clinical benefits for patients living with chronic liver disorders.
Source: Gilead Sciences press release
